REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Science & Research
5

CJC-1295 + Ipamorelin stack results

Charlie Chen 22·4 days ago
Posting my detailed log with before and after observations. I tracked everything meticulously including diet, sleep, exercise, and subjective well-being scores. Happy to answer questions.

Comments (4)

Harley Murphy 627·about 2 months ago

Interesting results. Have you considered adding blood work markers like CRP and IGF-1 to track systemic effects? That data could be really valuable.

2
Harley Johansson 727·about 1 month ago

Interesting results. Have you considered adding blood work markers like CRP and IGF-1 to track systemic effects? That data could be really valuable.

1
Harley Nakamura 827·20 days ago

Interesting results. Have you considered adding blood work markers like CRP and IGF-1 to track systemic effects? That data could be really valuable.

2
Harley Chen 27·4 days ago

Interesting results. Have you considered adding blood work markers like CRP and IGF-1 to track systemic effects? That data could be really valuable.

2

Sign in to comment.